Al-kawkab Scientific Bureau

Al-kawkab Scientific Bureau is a pharmaceutical importer based in Jordan, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Jordanian pharmaceutical distribution network, ensuring the availability of essential medications across the country. While specific details about its headquarters and parent company are not publicly disclosed, Al-kawkab Scientific Bureau's operations are integral to the healthcare supply chain in Jordan.

Al-kawkab Scientific Bureau's distribution network encompasses various regions within Jordan, facilitating the widespread availability of imported pharmaceutical products. The company collaborates with multiple logistics partners to ensure efficient transportation and delivery of goods. However, detailed information regarding specific warehouse locations and logistics capabilities is not publicly available.

In Jordan's pharmaceutical supply chain, Al-kawkab Scientific Bureau functions primarily as a wholesaler and importer. The company sources finished pharmaceutical formulations from international suppliers, notably from India, and distributes these products to various stakeholders within the healthcare sector, including hospitals, pharmacies, and clinics. This role is crucial in maintaining a steady supply of medications to meet the country's healthcare needs.

Al-kawkab Scientific Bureau exhibits a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier, MICRO LABS LIMITED, which accounts for 100% of its imports. This exclusive sourcing strategy may offer benefits such as streamlined procurement processes and potential cost advantages. However, it also introduces risks associated with dependency on a single supplier, including potential supply chain disruptions and limited negotiation leverage. The stability of this relationship is critical, and any changes in the supplier's operations or market conditions could significantly impact Al-kawkab Scientific Bureau's ability to meet market demand.

The resilience of Al-kawkab Scientific Bureau's supply chain is closely tied to its exclusive relationship with MICRO LABS LIMITED. The lack of backup suppliers and limited formulation diversity may pose challenges in the event of supply disruptions. Additionally, the company's reliance on a single shipping route and potential exposure to geopolitical risks could further impact supply chain stability. Ensuring regulatory compliance and maintaining a robust relationship with MICRO LABS LIMITED are essential to mitigate these risks.

Al-kawkab Scientific Bureau's sourcing pattern, characterized by exclusive reliance on MICRO LABS LIMITED, positions the company to benefit from streamlined operations and potential cost efficiencies. However, this strategy also exposes the company to significant risks associated with supplier dependency. For Indian exporters, this presents an opportunity to diversify their client base by offering alternative products or formulations that could appeal to Al-kawkab Scientific Bureau, thereby reducing the company's reliance on a single supplier and enhancing supply chain resilience.

The Jordan Food and Drug Administration (JFDA) is the primary regulatory authority overseeing the pharmaceutical sector in Jordan. The JFDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products through rigorous registration and monitoring processes. Key legislation governing pharmaceutical imports includes the Pharmaceutical Establishment Licensing Regulation No. 162 of 2019, which outlines the requirements for importing, distributing, and selling pharmaceutical products in Jordan. The marketing authorization pathway for Indian generics involves obtaining approval from the JFDA, which assesses the safety, efficacy, and quality of the products before granting registration.

Import licensing in Jordan is mandatory for pharmaceutical products. Importers must obtain an import license from the Ministry of Industry, Trade, and Supply, valid for one year. Additionally, the JFDA requires that imported pharmaceutical products be manufactured in facilities that adhere to Good Manufacturing Practice (GMP) standards recognized by reputable authorities, such as the European Medicines Agency (EMA) or the World Health Organization (WHO). Importers must ensure that their suppliers possess valid GMP certificates to comply with Jordanian regulations.

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with Jordanian standards. Stability studies are required to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in Arabic, providing essential information such as the product's name, active ingredients, dosage form, strength, manufacturing and expiry dates, storage conditions, and the manufacturer's details. Serialization may be mandated to enhance traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, the JFDA implemented stricter controls on the promotion and importation of pharmaceutical products. In August 2024, the JFDA issued new regulations to tighten controls on the promotion of specific medicines, aiming to ensure patient safety and prevent misuse. These regulations prohibit the promotion of any medicine before registration and restrict the dissemination of information not included in the official drug registration file. Additionally, in July 2025, the JFDA announced tighter regulations on the importation of pharmaceutical drugs, allowing patients to import a sufficient quantity of medications for personal use only after obtaining necessary approvals, thereby limiting the import of unregistered medications in commercial quantities.

Al-kawkab Scientific Bureau's product strategy focuses on three primary therapeutic categories: Advanced Antibiotics, Cardiovascular, and Advanced Diabetes Medications. The substantial import value of Advanced Antibiotics (67.3%) and Cardiovascular medications (30.1%) indicates a strategic emphasis on addressing prevalent health concerns in Jordan. The inclusion of Advanced Diabetes Medications (2.6%) reflects a commitment to managing chronic conditions that are increasingly common in the region. This product mix aligns with the market demand for effective treatments in these therapeutic areas.

Al-kawkab Scientific Bureau's sourcing strategy is heavily reliant on generic drugs, primarily imported from India. The company's exclusive relationship with MICRO LABS LIMITED suggests a preference for established suppliers that can provide a diverse range of formulations. This approach allows Al-kawkab Scientific Bureau to offer a comprehensive portfolio of pharmaceutical products to the Jordanian market.

Based on its product mix, Al-kawkab Scientific Bureau serves a broad segment of the Jordanian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential therapeutic areas positions it as a key supplier of critical medications, catering to both acute and chronic health conditions prevalent in the country.

There is a realistic opportunity for new Indian suppliers to engage with Al-kawkab Scientific Bureau by offering alternative products or formulations that complement the existing portfolio. Identifying gaps in the current sourcing strategy, such as unmet therapeutic needs or emerging market trends, can provide avenues for collaboration. However, any new supplier must be prepared to meet the stringent regulatory requirements set by the JFDA and demonstrate the ability to deliver high-quality products consistently.

Indian exporters seeking to supply Al-kawkab Scientific Bureau must ensure that their products are registered with the JFDA and manufactured in facilities adhering to recognized GMP standards. Compliance with Jordanian labeling requirements, including Arabic language specifications, is mandatory. Additionally, exporters should be prepared to provide comprehensive documentation, including certificates of analysis, stability data, and evidence of regulatory approvals from reputable authorities.

To establish a relationship with Al-kawkab Scientific Bureau, Indian exporters should initiate contact through formal channels, presenting their product portfolios and highlighting compliance with JFDA regulations. Participating in relevant industry trade fairs and conferences in Jordan can also facilitate networking opportunities. Understanding the regulatory filing process and preparing for the necessary approvals will be crucial. Given the competitive nature of the pharmaceutical market, a clear value proposition and commitment to quality will enhance the prospects of successful collaboration.